Genzyme in the UK

Company Info

Response Giving, Oxford-based mental health charity, receives charitable donation from Genzyme UK & Ireland

Date: July 31, 2015

Oxford, UK – Genzyme, a Sanofi Company, and has recognised the outstanding work of Oxford-based mental health charity, Response, with a £4,000 donation to its dedicated grant making arm, Response Giving. Response Giving provides grants to those living with mental health issues in the local community. Its roots go back to the 1960’s when a group of people met to see how they could help patients in the old Littlemore hospital. Requests to Response Giving are made by mental health professionals on behalf of clients they are supporting.

The Genzyme Corporate Social Responsibility (CSR) Team supports a single charity each year in the UK & Ireland with a small financial donation. In deciding which charities to support the Genzyme CSR Team considers how the request fulfils a compelling community need. The Genzyme CSR Team was impressed with the Response Giving Committee being made up of carers and services users which helps them target grants to clients with a specific need and, in addition, how recipients provided feedback on how the grant has improved the quality of their lives.

In receiving the donation Pat Armstrong Chairman of Response Giving said, “Thanks to Genzyme for considering Response Giving and encouraging us to a make an application for a charitable donation. Although individually small the grants provided by Response Giving make a huge difference to the lives of people living in the local community with mental health issues.”

John McLaughlin, Chief Executive of Response Organisation, added, “Fundraising for mental health charities is extremely challenging so it was great news to hear that Response Giving had been selected by Genzyme as its local charity for the year. We hope that this helps raise the profile of Response Giving and that we can support more people with severe mental illness and especially those living in some challenging social situations.”

“Genzyme has always been committed to supporting the local communities where our employees live and work and is proud to help organisations that serve critical community needs for vulnerable populations. We’re proud to support Response and the support services they offer to those living with mental health issues”, commented Brendan Martin, General Manager, Genzyme Therapeutics UK & Ireland.

About Response

Response Giving is the charitable fundraising arm of The Response Organisation, a leading provider of support services and housing to those who live with mental health issues. Response Giving is staffed entirely by volunteers and raises funds to directly support people with enduring mental health issues who are either in hospital or regaining their independence within the community. The funds are for the important little things that help make a big difference to daily life. Probably things that many of us take for granted but are out of reach to many of our beneficiaries. Response Giving fund an eclectic range of items - from a pair of winter boots (so somebody could keep their walking routine throughout the cold months) to purchasing new domestic appliances and from supporting a group to walk from coast to coast to buying a new TV for a ward. Everything funded by Response Giving makes a tangible difference. Response Giving does not ask for lengthy applications - just a short note asking what is needed, how much is required and how it will benefit the end-user usually suffices. We make considered, prompt and fair decisions based on the funds we have to hand. More on Response:

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents ground-breaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

About Genzyme in the UK

Genzyme is a significant force in the UK biotechnology sector focused on improving the lives of patients with rare genetic diseases and multiple sclerosis. First established in the UK in 1981, Genzyme employs 450 people at two sites. Genzyme Therapeutics in Oxford is the company’s UK commercial base marketing products for the treatment of patients with chronic debilitating diseases. These include genetic diseases such as lysosomal storage disorders (LSDs) – characterised by a lack of enzymes essential to healthy biological processes – and multiple sclerosis – a complex neurological disease affecting the central nervous system. Our portfolio also includes a therapy which aids in the management of thyroid cancer.

Genzyme’s manufacturing facility in Haverhill, Suffolk, now integrated with Sanofi’s Pharma Operations Unit, has undergone a dramatic building programme since its purchase in 1982 and now employs 380 people at a site with two large-scale manufacturing plants, a pilot plant, a development centre, warehouse and other associated facilities. The Haverhill facility manufactures the active ingredients in therapies for patients undergoing renal dialysis and is a major global distribution centre for Genzyme’s products for genetic diseases. Learn more at

Genzyme® is a registered trademark. All rights reserved.


Genzyme Media Relations (UK & Ireland)
Henry Featherstone – Genzyme
Mob: 07718 695 969

Rick Mower
Tel: 0790 999 3093
Mob: 07880 056 198


  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Tel: +01865 405200
Fax: +01865 774172

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Tel: +01440 703522
Fax: +01440 716269